General MedicationsOPHTHALMICStandard
OXERVATE
CENEGERMIN-BKBJ
Standard Dose
0.002%(20MCG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview OXERVATE is listed in Drugs@FDA under application 761094 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CENEGERMIN-BKBJ Form and strength SOLUTION;OPHTHALMIC - 0.002%(20MCG/ML) Sponsor DOMPE FARMACEUTICI Submission history Latest submission status date: 2023-10-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview OXERVATE is listed in Drugs@FDA under application 761094 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient CENEGERMIN-BKBJ Form and strength SOLUTION;OPHTHALMIC - 0.002%(20MCG/ML) Sponsor DOMPE FARMACEUTICI Submission history Latest submission status date: 2023-10-20 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.